was not observed. 2 Another large epidemiologic study analyzed trends in the incidence of diabetes-related complication from 1990 to 2010
and found a large relative decline of 67.8% in acute myocardial infarction (95% confidence interval [CI] , −76.2 to −59.3) among patients with diabetes. 3 However, even with significant progress patients with diabetes remain at elevated risk of cardiovascular morbidity and mortality. 3 Importantly, the excess mortality and comorbidity seen in patients with diabetes are more evident in patients who are younger, have poor glycemic control or have renal complications. 4 Observational data have shown that an increase in glycated hemoglobin level of 1% corresponds to a 15% increased risk of incident CVD. 4 There are some conflicting data in regards to cardiovascular outcomes from large studies that aimed to achieve excellent glycemic control. Data from the ACCORD trial showed increased mortality associated with intensive glucose control (glycated hemoglobin level below 6.0%), probably because of frequent hypoglycemic episodes associated with very strict glycemic control. 5, 6 Lack of benefit in cardiovascular mortality from intensive glucose control has also been confirmed by other large, randomized controlled trials, such as the ADVANCE and the Veterans Affairs Diabetes Trial. 7, 8 However, large trials, such as the UKPDS, have found reduction in myocardial infarction and death after 10 years of follow up with strict glucose control. 9 Therefore, it Amit K. Dey and Jacob Groenendyk contributed equally to this study.
appears there is a limit to the reduction of CVD burden that can be achieved by increasing the intensity of glucose control. While reaching glycated hemoglobin targets for all patients remains an important goal, other strategies for the prevention of CVD are needed. In this review, we discuss two relatively newer classes of medication for diabetes mellitus that have been increasingly recognized in recent years as agents that could assist in the prevention of CVD, namely SGLT-2 inhibitors and glucagon-like peptide 1 (GLP-1) agonists.
| SGLT-2 inhibitors
The first nonspecific SGLT inhibitor to come into medical use was phlorizin, which is extracted from the bark of apple trees. 10 Subsequently, it was discovered to cause glycosuria. 11 However, therapeutic use of phlorizin in diabetes was limited because of low oral bioavailability. 12 Investigators hypothesized that targeted inhibition of SGLT-2, the sodium-glucose cotransporter that resorbs 80% to 90%
of the 180 g of sugar daily filtered by the kidney, could improve glycemic control in diabetes. 13 Recently, specific inhibitors of SGLT-2, such as dapagliflozin, canagliflozin, and empagliflozin have been developed for glycemic control in diabetes. [14] [15] [16] Patients using SGLT-2 inhibitors typically see a mild reduction in blood pressure, mild weight loss (approximately 2 kg loss at 1 year for empagliflozin, compared to 0.5 kg gain on placebo), and a small increase in both HDL and LDL cholesterol. [17] [18] [19] [20] In addition, data from leptin-receptor deficient mice suggests that treatment with SGLT-2 inhibitors may decrease insulin resistance conferring additional benefits independent of glycemic control. 21 The most common known side effect of these drugs is an increase in urinary tract infections, although concerns have also been raised about increased rates of diabetic ketoacidosis, bone fractures, and bladder cancers. 22 Increased complaints of polyuria, associated with the osmotic diuresis phenomenon of SGLT-2 inhibitors, have also been documented, along with concurrent hemoconcentration. 22 Safety alerts have been issued by the US Food and Drug Administration (FDA) about the increased risk of decreased bone mineral density, leg or foot amputations (canagliflozin), and risk of ketoacidosis with SGLT-2 inhibitors. 23 In 2008, the US FDA suggested that new antidiabetic therapies be evaluated for associated alterations of cardiovascular risk, given concerns that specific glucose-lowering drugs might worsen cardiovascular outcomes (CVOs). 24, 25 Empagliflozin was the first novel SGLT-2 inhibitor with results on cardiovascular outcomes. The EMPA-REG OUTCOME trial (Table 1) , which randomized patients to receive 10 mg empagliflozin, 25 mg empagliflozin, or placebo once daily, was a multi-center trial that included 7020 adults at high cardiovascular risk (based on history of cardiovascular disease) and with glycated hemoglobin between 7.0% and 9.0% (or 10.0% if on stable glucoselowering therapy). 26 The primary outcome of EMPA-REG OUTCOME, which was a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, was significantly less likely to occur in the pooled empagliflozin group (10.5%) compared to the placebo group (12.1%, P = 0.04). The secondary outcome, cardiovascular death, occurred in 12.8% of patients in the empagliflozin group compared to 14.3% of the placebo group, although this difference was not statistically significant (P = 0.08). 26 Interestingly, there was not a significant change in the rate of myocardial infarction or stroke between the two groups; hospital admission for heart failure, however, was significantly less likely in the empagliflozin group (occurring in 2.7%) vs the placebo group (4.1%, P = 0.002). 26 After the first 12 weeks of the trial, during which glucose-lowering therapy was held stable, those in the empagliflozin group had glycated hemoglobin levels about 0.5 percentage points lower than those in the control group, with little difference between the 10 and 25 mg/day groups. 26 At 4 years, the difference between the empagliflozin groups and the placebo groups was about 0.3%, although adjustment of antiglucose medications was allowed after week 12. 26 Rates of serious adverse events, adverse events, and overall rates of urinary tract infection and pyelonephritis were similar between the empagliflozin groups and the placebo group, although adverse, severe adverse and serious adverse events, genital infections, and urinary tract infections were significantly more in the pooled empagliflozin group compared to the placebo group. 26 Subsequently, the effects of treatment with canagliflozin, another SGLT2 inhibitor on cardiovascular events were investigated in the CANVAS and CANVAS-R studies, which were published in combined form as the CANVAS Program (Table 1) . 27 The combined trials included 10 142 patients in 30 countries, with a minimum follow-up of 78 weeks (median 126 weeks). 27 Notably, while all CANVAS Program patients were at high cardiovascular risk based on the presence of risk factors, only 65.6% had history of cardiovascular disease, compared to >99% in the EMPA-REG OUTCOME trial. 27 Similar to the EMPA-REG OUTCOME study, participants treated with canagliflozin saw an average decrease of 0.6% in glycated hemoglobin and about 1.6 kg in body weight when compared to patients receiving placebo at follow-up. 27 The event rate for the primary outcome, a composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, was observed significantly less in patients randomized to canagliflozin than those randomized to placebo (drug vs placebo: events in 26.9 vs 31.5 participants per 1000 patient-years, hazard ratio (HR) 0.86, P = 0.02). 27 Event rates for the secondary outcome (death from any cause) did not statistically differ, at 17.3 vs 19.5 events per 1000 patient-years (P = 0.24). 27 Serious adverse events were more likely to occur in the placebo group, at 120.0 adverse events per 1000 patient-years, compared to the canagliflozin group, at 104.3 adverse events per 1000 patient-years (P = 0.04). 27 However, the canagliflozin group experienced a greater rate of amputation (6.3 vs 3.4 events per 1000 patient-years, P < 0.001); infection of male genitalia (34. Non-fatal stroke risk, with RR 1.3, was borderline increased (1.00-1.68, P = 0.049). Notably, over 50% of the participants included in this meta-analysis were from the EMPA-REG OUTCOME study.
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A recent meta-analysis that included 82 SGLT-2 trials and 1968 major cardiovascular events further confirmed that SGLT2 inhibitors were protective against major cardiovascular events, heart failure, as well as all-cause mortality. 34 When interpreting the effects of SGLT-2 inhibitors on cardiovascular outcomes it is important to consider the beneficial effects of concurrent antihypertensive therapies on these outcomes. The new 2017 ACC/AHA guidelines recommend a treatment goal of less than 130/80 mm Hg for patients with diabetes. 35 Although these studies were performed prior to the new hypertension guidelines in 2017, 36 most patients were on some degree of blood pressure control therapy. Approximately, 80% of patients in both the EMPA-REG OUTCOME and CANVAS Program studies were on a renin-angiotensin-aldosterone system modifying medication at baseline, with 65% and 54% on a beta blocker and 43% and 44% on a diuretic in each trial, respectively. Baseline systolic blood pressures were below the 2014 guidelines set by the eighth Joint National Committee (less than 140/90 mm Hg for those under 60 years, less than 150/90 mm Hg for those older than 60 years). 26, 27, 37 Once the new, lower goals for blood pressure treatment have been fully adopted, it will be important to reassess the effectiveness of the glucosemodifying medications described in this systematic review. Future investigation will be needed to elicit whether these beneficial effects of SGLT-2 inhibitors are still present in patients treated under the 2017 ACC/AHA guidelines. 35 The mechanism through which SGLT2 inhibitors affect changes in cardiovascular outcomes is not entirely known. It is suspected that, in addition to the decrease in glucose levels, small but favorable effects on other CV risk factors contribute. These include decrease in body weight, favorable modifications to lipid levels, and lower blood pressure. 29 It is unlikely that inhibition of the SGLT2 pathway has direct effects on cardiac tissue; while SGLT1 receptors have been demonstrated to be present in the heart, SGLT-2 receptors have not. 29 The precise mechanisms of the CV effects of SGLT2 inhibitors still remain to be fully understood. Ultimately, more mechanistic studies with longer follow-up are needed to understand the nature of CV effects and determine whether these cardioprotective effects are sustained.
| GLP-1 agonists
In 1964, Elrick et al showed that oral glucose administration stimulated greater insulin secretion than intravenous glucose administration. 38 These effects were later showed to be driven by gut-derived placebo. 44 72% of these patients had established cardiovascular disease at baseline; mean glycated hemoglobin level was 8.7%. 44 After a median of 3.8 years of follow up, 13.0% of patients in the liraglutide group had experienced MACE, compared to 14.9% in the placebo group (P = 0.01, HR 0.87). 44 While the overall rate of myocardial infarction was slightly lower in the liraglutide group (1.6 vs 1.9 per 100 patient-years in placebo, P = 0.046), no significant trends were observed in rates of fatal MI, stroke, or hospitalization for heart failure . 44 At 36 months, patients in the liraglutide group experienced an average decrease in weight of 2.3 kg more than those in the placebo group, in addition to a 1.2 mm Hg decrease in systolic blood pressure and an increase in heart rate of 3.0 beats per minute. Patients in the liraglutide group had elevated amylase and lipase compared to those in the placebo group, as well as a non-significantly elevated incidence of pancreatic carcinomas (0.3% vs 0.1%, P = 0.06). 44 Glycated hemoglobin levels in the liraglutide group were 0.40 percentage points lower than those of the placebo group . 44 The FIGHT trial evaluated the use of liraglutide in patients recently hospitalized with heart failure and reduced left ventricular ejection fraction and did not show any clinical benefit post heart failure hospitalization. 45 The LIVE trial evaluated the use of liraglutide on patients with advanced cardiomyopathy and chronic heart failure. This study not only confirmed prior results but also showed that liraglutide is associated with an increase in heart rate as well as more serious cardiac adverse events in patients with chronic heart failure and reduced left ventricular function. 46 Another independent GLP-1 agonist study, the ELIXA study, evaluated the effects of lixisenatide when compared to placebo in 6068
diabetes patients who had a history of myocardial infarction or hospitalization for unstable angina in the previous 180 days . 47 The primary outcome was a composite of cardiovascular death, myocardial infarc- Furthermore, the SUSTAIN-6 trial evaluated the effects on incidence of composite cardiovascular death, nonfatal stroke, and nonfatal MI of 0.5 mg or 1.0 mg of another GLP-1-agonist, semaglutide,
given once weekly against placebo in 3297 patients. 48 Seventy-two percent of patients had established CV disease at baseline, and mean glycated hemoglobin level was 8.7%. The primary composite outcome occurred in 6.6% of patients in the semaglutide group, compared to 8.9% in the placebo group (P = 0.02). 48 Rates of all-cause mortality and cardiovascular mortality were similar between both intervention and placebo groups; the rate of nonfatal stroke (0.80 per 100 personyears) was significantly lower than the placebo group (1.31/100
person-years , P = 0.04). 48 The mean glycated hemoglobin level, compared to the placebo group, decreased by 0.7 percentage points in patients in the 0.5 mg semaglutide group and 1.0 percentage points in the 1.0 mg semaglutide group (P < 0.001 for both). 48 Mean body weight at week 104 was 2.9 kg lower in the 0.5 mg group and 4.3 kg in the 1.0 mg group, compared to placebo; systolic blood pressure was reduced by 3.4 and 5.4 mm Hg vs placebo, respectively . 48 Treatment discontinuation in the semaglutide group was higher than that in the placebo group, largely driven by significantly increased incidence of nausea and vomiting in the semaglutide group. 48 Finally, the EXSCEL study tested the effects of 2 mg exenatide,
another GLP-1 agonist, administered once weekly against placebo on the incidence of cardiovascular death, nonfatal MI, or nonfatal stroke in 14 752 patients followed for a median period of 3.2 years. 49 73%
of enrolled patients had previous cardiovascular disease, and baseline glycated hemoglobin level was 8.0%. 49 Mean glycated hemoglobin level was 0.7 percentage points lower in the exenatide group at 6 months when compared to the placebo group (P < 0.001), though this difference did narrow over time. 49 The observed event rates for the primary outcome were 3.7 events/100 person-years for the exenatide group, compared to 4.0 events/100 person-years in the placebo group (P = 0.06). 49 There was not a significant difference in the incidence rate of serious adverse events between the two groups. 49 Even though overall mortality was lower in the exenatide treatment group, the investigators noted that the threshold for significance was not met with this outcome according to the pre-specified hierarchical analysis plan . 49 The mechanisms for improved CV outcomes with semaglutide and liraglutide but not with lixisenatide remain to be elu- . 50 This year, the HARMONY trial investigated almost 9500 patients treated with either albiglutide (which was removed from the market in 2017) or placebo for a median 1.6-year follow-up period. Albiglutide was shown to significantly reduce the risk of MACE by 22%; however, the study did not show a significant reduction in death from cardiovascular causes, as was demonstrated with liraglutide, another GLP-1 agonist in the LEADER trial. 51 This finding may be related to the short duration of follow-up in the study.
The ongoing REWIND trial is a randomized placebo-controlled trial which will test the cardiovascular effects of once-weekly dulaglutide, another GLP-1 agonist in patients with type 2 diabetes. The highlight of the trial is its high proportion of women and a predominantly primary prevention population. 52 Another ongoing trial PIONEER 6 is designed as a non-inferiority trial that will investigate the cardiovascular safety of oral semaglutide, another GLP-1 agonist compared with placebo. 53 Both these trials will provide important insight for regulatory approval of GLP-1 agonists.
Collectively, the overall signal that seems to emerge from the literature about the effects of these novel drugs is a positive effect on CV outcomes among patients at risk for structural heart disease, a lack of effects on heart failure outcomes among those with early cardiac remodeling, and possible detrimental effects on heart failure outcomes in patients with advanced symptomatic heart failure. 54, 55 The new ADA standards along with the EASD guidelines, recently recommended the use of SGLT2 inhibitors in patients with cardiovascular disease and diabetes. 56 Moreover, ACC consensus committee pub- 
